<DOC>
	<DOC>NCT02185924</DOC>
	<brief_summary>Combination of continuous femoral block with parEcoxib vs placebo. Investigation of morphine consumption, opioid sparing effects, VAS pain scores, haemodynamics, Anxierty scores, transfusion requirements , Range of motion and rehabilitation parameters between two groups</brief_summary>
	<brief_title>Combination of Continuous Femoral Block and Intravenous Parecoxib For Postoperative Analgesia After Total Knee Arthroplasty</brief_title>
	<detailed_description />
	<mesh_term>Ropivacaine</mesh_term>
	<mesh_term>Parecoxib</mesh_term>
	<criteria>PATIENTS ASA III UNDERGOING TOTAL KNEE ATRTHROPLASTY Exclusion criteria for both groups included: Age younger than 40 years old or older than 80 years old ASA &gt; III Obesity (&gt;140 kg body weight) Allergy to local anesthetics History dependence on opioids Contraindications for subarachnoid anesthesia or femoral block (coagulopathy, local infection, preexisting neurological problems, patient refusal) Contraindications to the administration of parecoxib Severe hepatic or renal disease (serum creatinine â‰¥ 1.7 mg/dl)</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>PARECOXIB</keyword>
	<keyword>CONTINUOUS FEMORAL BLOCK</keyword>
</DOC>